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ABSTRACT
During treatment of acute heart failure (AHF), worsening renal function is often complicated and results in a complex clini-
cal course. Furthermore, renal dysfunction is a strong independent predictor of long-term adverse outcomes in patients with 
AHF. Traditionally, the predominant cause of renal dysfunction has been attributed to impairment of cardiac output and 
relative underfilling of arterial perfusion. Recently, emerging data have led to the importance of venous congestion and ele-
vated intra-abdominal pressure rather than confining it to impaired forward cardiac output as the primary driver of renal im-
pairment. Relief of congestion is a major objective of AHF treatment but therapy is still based on the administration of loop 
diuretics. The results of the recently performed controlled studies for the assessment of new treatments to overcome resist-
ance to diuretic treatment to protect kidneys from untoward effects have been mostly neutral. Better treatment of congestion 
in heart failure remains a major problem. (Korean Circ J 2011;41:565-574)
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Introduction
Acute heart failure (AHF) is a major source of hospitaliza-
tion and mortality. Patients with AHF usually present with se-
vere dyspnea due to pulmonary congestion which is the hall-
mark of AHF. Therefore, elimination of excess fluid should 
be the primary target of treatment. Also, there is substantial 
evidence that fluid accumulation is associated with morbidity, 
mortality, and readmission with heart failure (HF).
1-4) Kidney 
is the main exit of congestion, but many numbers of AHF pa-
tients have accompanying renal dysfunction or experienced 
worsening of renal function during hospitalization. The he-
art and kidney are very closely related. Thus derangement of 
cardiac function can make renal dysfunction, recently re-
ferred to as “cardiorenal syndrome (CRS)” or inversely as “re-
nocardiac syndrome”. In 2008, Ronco et al.
5) classified CRS 
into 5 subtypes, as showed in Table 1, by primarily affected or-
gan (heart or kidney) and course of injury (acute or chronic). 
By this classification, type 1 CRS, which is the development 
of renal dysfunction in clinical situation of AHF, is the topic of 
our discussion and has been found to be more prevalent in 
hospitalized AHF patients. 
Although, it is well established that patients who are ad-
mitted with AHF and renal dysfunction have worse outcomes, 
there is limited data for evidence-based therapeutic appro-
aches.
6-8) This is most likely because AHF is not a specific cli-
nical-pathologic event and is not caused by a well-defined pa-
thophysiologic mechanism (like acute coronary thrombosis), 
but instead results from various factors. AHF patients may 
manifest either 1) rapid accumulation of fluid in the lung, 2) 
progressive systemic congestion, or 3) clinical findings asso-
ciated with reduced cardiac output. In addition, it is very dif-
ficult to test the impact of specific interventions, because these 
patients are inherently unstable and there are so many avail-
able treatment options and lack of appropriate target end-
points. For these reasons, there is a paucity of useful clinical 
trial evidence in patients with AHF, which results in a situa-
tion where most guideline recommendations for managing 
this syndrome are derived from “expert” opnions, unsupport-
ed by solid outcome data.
9-11)
However, there is continuous accumulation of clinical data 
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gement for AHF and accompanying renal dysfunction. In this 
review, we discuss the pathophysiology of renal dysfunction 
associated with AHF, early detection modalities, and finally, 
current therapeutic strategies. We used the terminology “re-
nal dysfunction in AHF” rather than “CRS”. As noted above, 
some authors used the “CRS” in a variable clinical situation, 
but our point of discussion is focused on renal dysfunction in the 
setting of AHF, especially worsening during AHF treatment. 
Prevalence and Prognosis
Accompanying renal dysfunction
American College of Cardiology/American Heart Associ-
ation guidelines for “HF data standard” suggested that chronic 
renal disorder can be categorized in to 4 groups as mild, mo-
derate, severe renal insufficiency and chronic renal failure by 
using the estimated glomerular filtration rate (eGFR); 60-89, 
30-59, 15-29, <15 mL/min/1.73 m
2 respectively.
9) Although, 
GFR can be estimated by various formulas, simplified Modi-
fication of Diet in Renal Disease (MDRD) formula (186.3× 
sCr
-1.154×age
-0.203, female: MDRD×0.742, Black or non-white: 
MDRD×1.212) is simple, and only serum creatinine and age 
are needed for calculation. It is also a reliable predictor for 
prognosis in HF patients.
12) It is not appropriate to use a single 
measurement of serum creatinine for the evaluation of renal 
function, because serum creatinine levels can be largely in-
fluenced by age, muscle mass etc. However, many clinical tri-
als and registry data used serum creatinine levels for the diag-
nosis of renal dysfunction. 
In large nationwide registry data in USA and Europe, 20.4% 
of patients had serum Cr >2.0 mg/dL in Acute Decompensat-
ed Heart Failure National Registry (ADHERE), and 18% in 
EURO-Heart survey (40% in old EU). In Korean Heart Fail-
ure (Kor-HF) registry, 15.2% of AHF patients showed level 
of serum Cr >2.0 mg/dL.
1)2)13) In the Evaluation Study of Con-
gestive Heart Failure and Pulmonary Artery Catheterization 
Effectiveness (ESCAPE), the proportion of patients with an 
eGFR <60 mL/min was 31.4%.
14)
Accompanying renal dysfunction is one of the main inde-
pendent risk factors for prolonged hospitalization, rehospita-
lization, and short- and long-term mortality.
6-8) In patients with 
HF, compared to left ventricular ejection fraction (LVEF) or 
NYHA functional class, baseline GFR has been demonstrated 
to be a stronger predictor for all-cause mortality. Likewise, a 
decrease in GFR is directly associated with the rate of in-hos-
pital mortality. In a meta-analysis, Smith et al.
15) reported that, 
annual mortality rates were 26% in patients without renal dys-
function, 41% in the patients with any impairment of renal 
function and 51% (p<0.001) in patients with moderate to se-
vere impairment (p<0.001).
Worsening renal function
Patients hospitalized for AHF often develop worsening re-
nal function. It occurs in 25-30% of acute HF admissions and 
is more likely in patients with renal dysfunction at baseline, 
diabetes and previous HF.
16-19) In Kor-HF registry, worsening 
of renal function, defined as increasing serum creatinine le-
vels more than 1.5 times baseline, happened in 21.5% of AHF 
patients.
13) Although there is no concrete criteria, worsening 
renal function is often defined as an increase in sCr ≥0.3 mg/ 
dL from baseline value. In a meta-analysis, prior mentioned, of 
16 studies including 80,098 patients, worsening renal func-
tion was associated with a 47% increase in one-year mortality, 
with a 33% increase in mortality for every 1 mg/dL increase 
in sCr. 
Forman et al.
16) reported that from 1,004 AHF patients, 
worsening renal function was related with 7.5 times higher 
relative risk ratio for in hospital death and 2.1 times higher 
for complication. In Kor-HF registry, in-hospital mortality 
was significantly higher (13.2% vs. 5.4%, p<0.01) and duration 
of intensive care unit (ICU) stay and hospitalization were 
prolonged in patients with worsening renal function.
13)
Sometimes, worsening renal function dose not persist, but 
in two-thirds of this condition could to be persist and associat-
ed with worse outcomes. Due to confounding factors (etiolo-
gy, co-morbidities, medications etc.) and baseline renal func-
Table 1. Classification of CRS
Type Character Proposed mechanism Clinical setting
Type 1 Acute CRS
Abrupt worsening of cardiac function 
  leading to kidney injury
Acute cardiogenic shock, acute 
  decompensated HF 
Type 2 Chronic CRS
Chronic cardiac abnormalities causing 
  progressive chronic kidney injury
Chronic heart failure cause chronic 
  renal hypoperfusion
Type 3 Acute renocardiac syndrome
Abrupt worsening of renal function 
  causing acute cardiac disorder
ARF, Acute GN cause acute pulmonary 
  edema, arrhythmia 
Type 4 Cronic renocardiac syndrome
Chronic kidney disease contributing 
  to decreased cardiac function
Chronic renal disease cause cardiac 
  hypertrophy, decreased cardiac function
Type 5 Secondary CRS
Systemic condition causing both cardiac 
  and renal dysfunction
Diabetes, sepsis 
CRS: cardiorenal syndrome, HF: heart failure, ARF: acute renal failure, GN: glomerulonephritisSeong Woo Han, et al.   567
tion, the real impact of worsening renal failure on prognosis 
is unclear. Additionally, the lack of a clear definition of wors-
ening renal function, and heterogeneity of currently available 
biomarkers of renal function provide a limitation for the in-
terpretation of these results. 
Pathophysiology
Heart failure is characterized by complex cardiac, renal, 
and vascular interactions, mediated through both hemody-
namic and neurohumoral mechanisms (Fig. 1). Increased 
vascular stiffness limits the ability of the intravascular space 
to accomodate salt and fluid loads. Endothelial dysfunction 
contributes to vasoconstriction and increased afterload. Re-
nal dysfunction may limit sodium excretion and drives acti-
vation of the renin-angiotensin-aldosterone axis. Although, 
it is not yet clearly identified the mechanism of progressive 
renal dysfunction in AHF, following factors are proposed as 
pathophysiologic alterations of this syndrome. 
Hemodynamic abnormalities
Low cardiac output
Patients with HF may progress to a chronic low cardiac out-
put state with systemic and renal hypoperfusion and cause 
activation of rennin-agiotensin-aldosterone system (RAAS) 
and sympathetic sympathetic nervous system (SNS) leading 
to sodium retention, volume expansion and ventricular remo-
deling.
20)21) Theoretically, the progressive impairment of renal 
function may result from inadequate renal perfusion secon-
dary to reduced cardiac output. However, several data sug-
gest that hemodynamic alteration from low cardiac output is 
not the only determinant of reduced GFR, and management 
of patients with CRS based only on improvement of renal blo-
od flow does not lead to a better prognosis.
22) This hypothe-
sis is supported by the observation that renal dysfunction oc-
curs at similar rates in patients with either systolic or diastolic 
dysfunction.
23) 
Elevated central venous pressure 
Basically, the pressure gradient between glomerular afferent 
and efferent arterioles makes the drive force for glomerular 
filtration. In HF patients, increased central venous pressure 
(CVP) can be transmitted to the glomerular efferent arteriole 
with a reduction of the glomerular filtration pressure gradient 
and cause a fall of GFR. Additionally, it was postulated that 
transmitted pressure to the renal vein causes increased renal 
interstitial pressure and this may lead to renal parenchymal 
hypoxic state. In practical terms, Mullens et al.
24) reported that 
in 145 patients of AHF, only the CVP was the most important 
determinant of the development of worsening renal function. 
In addition, Damman et al.
25) found that CVP was the most im-
portant determinant of renal dysfunction and the most im-
portant independent predictor of mortality in 2,557 patients 
hospitalized for cardiac catheterization. Notably, elevated jug-
ular venous pulsations on physical examination and baseline 
right atrial pressure are related with elevated baseline serum 
creatinine.
26) Recently, further studies have demonstrated that 
CVP has a close relationship with renal dysfunction in patients 
with HF.
27)28) 
Adenosine 
Adenosine is released in response to increased sodium lo-
ading in the distal tubule, and via A1-receptors in the proximal 
tubule and afferent arterioles, mediates constriction of afferent 
arterioles and reduction of renal blood flow and GFR. Addi-
tionally, activation of A1 receptors induces release of rennin 
and enhances sodium re-absorption at the proximal tubule 
and reduces diuresis.
29) Thus, adenosine may be an important 
mediator for renal dysfunction after intensive diuretic treat-
ment with high dose loop diuretics for AHF. Unfortunately, 
studies with type 1a-adenosine receptors blocking agents have 
failed to demonstrate a significant beneficial effect in renal 
function in AHF.
30)
Fig. 1. Pathophysiological mechanisms of worsening renal function in acute heart failure.
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Neurohumoral mechanism
When HF develops, RAAS and SNS are activated as a pro-
tection mechanism for renal hypoperfusion.
31)32) This is es-
sential in dangerous situations like gastrointestinal bleeding 
or trauma. However, in the case of chronically stimulated state, 
the consequence of these conditions is deleterious on the heart 
and kidney. 
Increased renin secretion is demonstrated in HF and gen-
eration of angiotensin II from angiotensin I is enhanced by 
rennin. Angiotenin II is a potent constrictor of arterioles and 
therefore increases the afterload resulted in decreased cardi-
ac output. Angiotenin II stimulates the SNS and aldosterone 
release as well, and these cause further constriction of renal 
vasculature. Constriction of afferent arterioles by angioten-
sin II and SNS reduces renal blood flow and GFR, and cau-
ses increased proximal tubular sodium reabsoprtion.
32)33)
Activation of SNS initially has a protective role for mainta-
ining cardiac output by positive chronotropic and inotropic 
effects. Like RAAS activation, chronic activation of SNS also 
resulted in numerous deleterious effects on the cardiovascu-
lar system and kidneys.
34) In the kidney, activation of SNS also 
causes further activation of RASS and leads to inadequate 
fluid and sodium retention. Reduced renal perfusion pressure 
during HF causes constriction of afferent arterioles, and a fur-
ther decrease in renal blood flow and GFR. When HF devel-
ops, these effects are more exaggerated due to higher release 
and lower clearance of catecholamines. 
Arginine vasopressin (AVP) is released by osmotic stimuli, 
blood pressure, and cardiac factors. In usual situations, low 
osmolarity suppresses AVP release, but in HF state, due to 
non-osmotic baroreceptor mechanisms, there is a marked in-
crease in AVP release even with hyponatremia. AVP activates 
the V2 receptor in the collecting duct and increases the per-
meability of water channels resulting in water retention. AVP 
stimulates the V1a receptors of the vascular smooth muscle 
that results in vasoconstriction of the arterial and venous 
system.
35-37)
Evaluation of Renal Dysfunction
Conventional markers (blood urea nitrogen, 
creatinine)
Usually, evaluation of renal dysfunction is based on change 
of serum creatinine (sCr). However, there are many limita-
tions in using sCr as a marker of renal dysfunction. Serum 
creatinine is largely influenced by age and related to other va-
riables including sex and muscle mass.
38)39) Additionally, sCr 
level is not sensitive for the detection of renal injury. It is de-
monstrated that, kidney damage can occur without produc-
ing a change in eGFR calculated by sCR. The amount of ch-
anges in serum creatinine after renal injury is highly depend-
ent on baseline kidney function: in case of normal baseline 
renal function, sCr levels start to increase at advanced stage 
of renal injury, whereas when renal dysfunction is already 
present, it can be overestimated due to the sCr level changing 
a relatively large amount (e.g., 50% increase in sCr with base-
line level 1.0 mg/dL and 2.0 mg/dL result in 1.5 mg/dL and 
3.0 mg/dL respectively).
40) Also, there is an exponential rela-
tionship between sCr level and estimated GFR, therefore, wor-
sening renal function may be better defined by either an abso-
lute increase from baseline and a percent increase. Recently, 
it has been reported that renal dysfunction defined as both a 
≥0.3 mg/dL increase plus ≥25% increase from baseline val-
ues was an independent prognostic factor, whereas it had no 
independent prognostic value when defined only by abso-
lute changes from baseline.
19)
Because sCr has slow kinetics, marked reduction in eGFR 
may cause relatively small changes in sCr levels in the early 
stage of acute kidney injury (24-48 hours). In addition, sCr 
kinetics are dependent on baseline renal function so that the 
time interval from kidney injury to 50% increase in sCr rang-
es from 4 hours with normal baseline renal function to more 
than 1 day with underlying advanced renal dysfunction.
41) 
More importantly, sCr level is a marker of renal function ra-
ther than kidney injury, so, increased sCr levels are not al-
ways representative of kidney injury. 
Blood urea nitrogen (BUN) was shown to be an important 
predictor of morbidity and mortality in patients with HF.
8)42-44) 
The major difference between sCr and BUN is related to the 
reabsorption of BUN in the renal tubules. It is mediated by 
AVP, sympathetic nervous activity, renin-angiotensin-aldo-
sterone system and to sodium reabsorption with volume sta-
tus.
45) Therefore, intensive diuretic treatment, enhance urea 
reabsorption and increase BUN. Recently, Testani et al.
46) re-
ported that, in Beta-blocker Evaluation of Survival trial, ele-
vated serum BUN level with high dose loop diuretics was as-
sociated with high mortality in chronic HF (Fig. 2). BUN is 
also dependent on nitrogen production and in conditions 
causing an increase in protein catabolism, such as cachexia 
and gastrointestinal hemorrhage.
47)
Novel markers
Neutrophil gelatinase-associated lipocalin
Neutrophil gelatinase-associated lipocalin (NGAL) is the 
most promising emerging biomarker for acute kidney injury. 
In humans, NGAL is a small 25 kDa 178 amino acid chain, 
expressed by neutrophils and other epithelial cells in the pro-
ximal collecting tubule.
48) The physiological role of NGAL in 
renal ischemia or toxin induced kidney injury, may be to de-
crease injury by reducing apoptosis and increasing the nor-
mal proliferation of kidney tubule cells. It is freely filtered by 
the glomerulus and completely reabsorbed in the tubules. 
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the ability of NGAL to allow early identification of acute kid-
ney injury, including cardiac surgery, contrast studies, ICUs 
and the emergency department.
49) In patients with acute HF, 
NGAL can predict worsening renal function more accurately 
in an earlier stage than sCr. Aghel et al.
50) reported that in 91 
patients admitted for AHF, worsening renal function was ob-
served in 38% within 5 days of follow-up. Patients who devel-
oped worsening renal function had significantly higher me-
dian serum NGAL levels (194 ng/mL vs. 128 ng/mL, p=0.001) 
at admission and it was associated with an increase in risk of 
developing worsening renal function.
50) Levels of urinary NGAL 
may be more sensitive as makers for tubular damage than 
serum levels. However, more studies are needed to confirm 
its usefulness in clinical practice and provide exact cut-off 
levels for different clinical settings.
Cystatin C
Cystatin C (CysC) is a 13.3 kDa, 122-amino acid protein, 
member of the superfamily of cysteine protease inhibitors, 
and is synthesized by all nucleated cells at a constant produc-
tion rate. It is freely filtered by the glomerulus, and not se-
creted but slightly metabolized by tubular epithelial cells. 
Compared with sCr, CycC has been demonstrated to be in-
dependent of age and sex.
51)52) Thus, serum CysC would be 
one of the ideal markers to estimate GFR. It has been dem-
onstrated that CysC is a more sensitive marker than SCr for 
small changes in GFR and could be an earlier indicator of 
mild renal failure. In patients with AHF, CysC is an indepen-
dent factor for longer length of hospitalization (p=0.01) and 
higher in-hospital and post-discharge mortality. Interestingly, 
elevated serum CysC is associated with higher mortality at 
12 months in patients with normal sCr level (p<0.0001).
53)
 
Other biomarkers
Kidney injury molecule-1 (KIM-1) is a transmembrane pro-
tein expressed in proximal tubule cells during renal diseases 
associated with either proteinuria, toxic or ischemic damage. 
It is expressed in post-ischemic kidneys while remaining un-
detectable in healthy subjects, and showing that it expresses 
during tubule-interstitial injury and inflammation. Urinary 
KIM-1 levels correlate with tubular KIM-1 expression in expe-
rimental models and in human renal disease.
54) In chronic HF, 
KIM-1 demonstrated a correlation with plasma N-terminal 
pro-brain natriuretic peptide (BNP) levels and, independent-
ly of GFR values, was associated with an increased risk of 
death or HF hospitalizations. KIM-1 is highly sensitive to acu-
te tubular injury but in the setting of acute HF its role is still 
unsettled.
56) 
N-acetyl-beta-D-glucosaminidase (NAG) is produced in the 
proximal tubule and after tubular injury, released into the 
urine. In patients with HF, urinary NAG levels, as KIM-1, 
were associated with plasma N-terminal pro-BNP levels and 
increased risk of death or HF hospitalizations regardless of 
GFR.
55) In addition, NAG levels were correlated with GFR 
(p=0.001) and effective renal plasma flow (p=0.006), suggest-
ing that this marker can detect decreased renal perfusion in 
patients with low cardiac output As for KIM-1, data in AHF 
are lacking. The accuracy of this marker in acute kidney in-
jury suggesting its usefulness in the acute setting and further 
studies are needed in order to define its role in AHF. Other 
novel protein biomarkers for the early detection of kidney 
are listed and briefly introduced in Table 2.
Treatment
In patients with acute HF, markedly activated neurohor-
monal axis and worsening renal function ultimately ensue to 
venous congestion and elevated CVP, which results in a vi-
cious cycle. Thus, the focus of the treatment should be on re-
ducing the congestion with as little hemodynamic compro-
mise as possible. 
Relief of congestion
Diuretics
Current practice guidelines recommend loop diuretics as 
the mainstay of therapy in patients with congestive symptoms 
in the setting of AHF.
11) In ADHERE registry, 88% of patients 
receive loop diuretics, mainly intravenously.
1) There are no 
randomized controlled trials to evaluate the beneficial effects 
of loop diuretics. However, it is evident that congestion corre-
lates with mortality, therefore, patients with AHFS should be 
treated for the relief of congestion. In patients who have se-
Fig. 2. Adjusted survival plots grouped by BUN and high dose loop 
diuretics use.
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vere congestion and renal dysfunction, diuresis may improve 
kidney function, possibly through relieving the central venous 
congestion. What is more beneficial for controlling conges-
tion intermittent versus bolus, or high dose versus conven-
tional dosage of loop diuretics is a recurring question. The 
Diuretic Optimization Strategies Evaluation (DOSE) trial is 
the first randomized, controlled exploration of a management 
strategy in loop diuretics in AHFS patients. In this study, there 
was no statistically significant difference in symptom relief or 
renal function at 72 hours between intermittent versus con-
tinuous infusion or low dose versus high dose strategy.
56)
There are several mechanisms for diuretic resistance: inad-
equate dose, excess sodium intake, delayed intestinal absorp-
tion, decreased excretion of diuretics at action site, vigorous so-
dium reabsorption at other sites of nephron (Table 3). Experts 
recommend switching from intravenous to continuous infu-
sion in patients who seem to be nonresponsive to diuretics. 
Although, for the relief of congestion and symptoms, loop di-
uretics are very effective, it should be considered that there 
are serious adverse effects associated with loop diuretics.
57) El-
ectrolyte abnormalities mainly hyponatremia, hypokalemia 
and hypomagnesemia are frequently developed with these 
agents. The loop diuretics can cause increased release of renin 
and further stimulation of neurohormones and acute vaso-
constriction after administration, so, even though urine out-
put is substantially increased GFR can be reduced by loop 
diuretics induced vasoconstriction.
58) Another approach to 
overcome diuretic resistance is limitation of total daily sodi-
um intake to less than 2 gm, and fluid restriction of less than 
2 liters. When moderate hyponatremia (<130 mEq/L) exists, 
the patient should be educated for more aggressive fluid re-
striction. The pharmacologic approach to overcome resist-
ance is to add another diuretic that acts in distal tubule, such 
as a thiazide or metolazone. Continuous infusion of loop di-
uretics may avoid rebound absorption of sodium that occur 
when serum levels of loop diuretics are low or reduce ototo-
xicity. But, as stated above, in the DOSE trial, there was no 
difference in outcome of mortality.
Vasopressin antagonist
Patients with acute decompensated HF often have an acti-
vation of AVP release. AVP causes water retention via vaso-
pressin type 2 (V2) receptors in the collecting duct. The V2 re-
ceptor antagonists-“vaptans”-can induce free water diuresis 
and correction of hyponatremia in patients with HF. In Effica-
cy of Vasopressin Antagonism in Heart Failure Outcome Stu-
dy With Tolvaptan trial, the efficacy of the selective V2 recep-
tors antagonist, tolvaptan has been evaluated with 4,133 pa-
tients with HF for the outcomes, and symptoms/signs of HF. 
Compared to placebo, tolvaptan was associated with greater 
improvement of symptoms, but no benefit on outcomes. There 
was no derangement of renal function throughout the study.
59) 
Other studies conducted on subjects with chronic HF showed 
neutral effects of vasopressin antagonists on renal function 
compared with furosemide.
60) Therefore AVP antagonists can 
be applied in the limited setting of HF patients with hypona-
tremia. However, antagonists for V2 receptors are not yet av-
ailable in Korea. 
Adenosine antagonists
As mentioned above, adenosine has a detrimental effect on 
renal hemodynamics. On the basis of this pathophysiological 
concept, adenosine A1 receptor antagonists have been inve-
stigated in patients with advanced HF. Many relatively small, 
controlled studies have been conducted for the evaluation of 
adenosine receptor antagonists including BG9719, KW-3902 
(rolofylline), and could find renoprotective effects of A1 re-
ceptor blockers. Based on these results a large-scale controll-
ed trial (PROTECT trial) was designed. In this trial, renal 
function was included among the components of the prima-
ry endpoint. Unfortunately, the results of PROTECT were neu-
tral for the primary endpoint (dyspnea relief combined with 
the absence of worsening HF at 1 week and worsening renal 
function at 7 and 14 days) and for the pre-specified secondary 
outcomes (death from any cause or rehospitalization for car-
diovascular or renal causes through day 60 and the propor-
tion of patients with persistent renal impairment).
30) In con-
Table 2. Protein biomarkers for the early detection of acute kid-
ney injury
Biomarker Associated injury
Cystatin C Proximal tubule injury
KIM-1 Ischemia and nephrotoxins
N-GAL (lipocalin) Ischemia and nephrotoxins
NHE3 Ischemia, pre-renal, post-renal AKI
Cytokines (IL-6, IL-8, 
  IL-18)
Toxic, delayed graft function
Actin-actin 
  depolymerizing F
Ischemia and delayed graft function
α-GST Proximal tubule injury, acute rejection
π-GST Distal tubule injury, acute rejection
L-FABP Ischemia and nephrotoxins
Netrin-1 Ischemia and nephrotoxins, sepsis
Keratin-derived 
  chemokines
Ischemia and graft function
GST: glutathione S-tranferase, KIM: kidney injury molecules, L-
FABP: L-type fatty acid binding protein, NGAL: neutrophil gelati-
nase-associated lipocalin, NHE: sodium-hydrogen exchanger
Table 3. Causes of resistance to furosemide
Inadequate diuretic dose
Excess sodium intake
Delayed intestinal absorption of oral diuretics
Delayed diuretic excretion into the urine
Na+ reabsorption at diuretic-insensitive site in the nephronSeong Woo Han, et al.   571
clusion, the administration of rolofylline was not associated 
with favorable effects on renal outcomes. An important issue 
in the PROTECT trial was the excess of neurological compli-
cations observed in the rolofylline group. Therefore, adenos-
ine receptor antagonist can not be recommended in HF pa-
tients with renal dysfunction. 
Correction of hemodynamic abnormalities
Dopamine
When administered at low doses (≤2 μg/kg per min), do-
pamine may selectively improve renal blood flow through 
its action on DA1 receptors. Also, improvement of diuresis 
can be expected, even though small but favorable changes in 
renal function by administration of low dose dopamine occur. 
At intermediate doses (2-5 μg/kg per min), dopamine inter-
acts with the β1-receptor, producing positive inotropic effects; 
this increase in cardiac output may be another favorable me-
chanism of the action of dopamine.
61)62) In the recently com-
pleted Dopamine in Acute Decompensated Heart Failure 
(DAD-HF) trial, 60 patients with acute HF were randomly as-
signed to continuous 8 hours infusion of high-dose furose-
mide (20 mg/h) or low-dose furosemide (5 mg/h) plus low-
dose dopamine (5 mcg/kg/min). Both strategies had similar 
effects on hourly diuresis and dyspnea score. Worsening renal 
function was more frequently observed in the high-dose di-
uretic group (30%), than in the dopamine group (6.7%) (p= 
0.042).
63) Length of hospitalization and 60-day mortality or 
rehospitalization rates were similar between both groups. Even 
though the favorable outcome was observed, the small sample 
size and no favorable effect on major outcome (mortality, re-
hospitlalization and free from renal replacement therapy), it 
can not be directly applied as evidence. 
Other inotropics 
Because renal hypoperfusion due to low cardiac output 
can contribute to renal dysfunction in acute HF, administra-
tion of inotropic agents might be useful. Dobutamine admi-
nistration has been associated with an increase of diuresis and 
natriuresis, and these effects are likely caused by the increase 
in cardiac output.
64) Recently reported data showed that in 88 
patients with acute HF randomized to levosimendan or do-
butamine, only levosimendan administration was associated 
with an improvement in measured eGFR (+15 and +45% from 
baseline after 24 and 72 hours, respectively), whereas there 
was no change in the dobutamine group.
65) However, these 
data were obtained in small, single-center studies, and were 
not confirmed in the large Survival of Patients With Acute 
Heart Failure in Need of Intravenous Inotropic Support (SUR-
VIVE) trial.
66)
There are possible suggestions to improve of renal function 
not related with increased cardiac output but associated with 
relief of venous congestion and decreased intra-glomeluar pres-
sure. The absence of clinical benefit associated with increased 
cardiac index was shown in the Outcomes of a Prospective 
Trial of Intravenous Milrinone for Exacerbations of Chronic 
Heart Failure study, and in the ESCAPE trial, which found 
no association between baseline renal function and cardiac 
index.
8)14) These results seem to confirm that, increased renal ve-
nous pressure and intraglomerular pressure, but not low car-
diac output, could be the main determinants of renal dysfunc-
tion and diuretic resistance, and therefore represent the thera-
peutic target, whereas inotropic agents should not be the tr-
eatment of choice for this condition. 
IV vasodilators
Intravenous vasodilators-nitrates and sodium nitroprus-
side-are frequently administrated, in patients with AHF with 
normal or high blood pressure. In KoHF registry, 35.8% of 
patients were treated with intravenous nitrate infusion.
13) At a 
low dose, nitroglycerin dilates venules and decreases cardiac 
filling pressures and myocardial oxygen demand; at higher 
doses, it decreases afterload and augments cardiac output. So-
dium nitroprusside acts on vascular smooth muscle, and in-
duce arterial and venous vasodilation.
67)68) Although, in patients 
with HF, nitrates and sodium nitroprusside do not have a di-
rect influence on fluid overload and do not improve renal blo-
od flow, compared with high doses of furosemide alone, treat-
ment with nitrates added to low doses of furosemide has been 
shown to be associated with better outcomes in patients with 
acute HF and normal to high blood pressure. Relaxin causes 
systemic and renal vasodilatory effects via nitric oxide path-
ways and the endothelin type B receptor, lead to systemic and 
renal vasodilation and increased arterial compliance; trigger-
ing similar changes could potentially be beneficial in the treat-
ment for patients with HF.
69)
On the basis of small sized data, a preliminary double blind, 
placebo-controlled, parallel group, dose-ranging study of re-
laxin for the treatment of patients with acute HF (Pre-RELAX-
AHF) was designed to assess the effect of intravenous relax-
in compared with placebo in 234 patients with acute HF, and 
mild-to-moderate renal insufficiency. Despite previous data 
suggesting favorable effects on GFR and renal blood flow, 
relaxin did not show a clear effect on renal function, although 
a greater weight loss with less diuretic use was noted. The on-
going RELAX-AHF study will provide more elements. 
Nesiritide 
Nesiritide is a recombinant human BNP and can be catego-
rized as a vasodilator. It enhances peripheral vasodilation, na-
triuresis, and diuresis through activation of guanylate cyclase 
pathways; moreover, it antagonizes the effects of the renin-an-
giotensin system, endothelin, and catecholamines. In the 
United States and other countries, it is approved for the treat-572   Renal Dysfunction in Acute Heart Failure
ment of congestive symptoms, in addition to diuretics, in 
patients with acutely decompensated HF. However, a subse-
quent meta-analyses of randomized trials evidenced untow-
ard effects of nesiritide on renal function and mortality. In 
particular, patients with acute decompensated HF nesiritide 
significantly increased the risk of worsening renal function. 
Recently, the Acute Study of Clinical Effectiveness of Ne-
siritide in Decompensated Heart Failure (ASCEND-HF) trial 
was performed to assess the effects of nesiritide on symptoms 
and outcomes of patients with acute HF. This study included 
7,141 patients with acute decompensated HF, randomized 
to placebo or nesiritide. Unfortunately, it did not meet the 
pre-specified criteria for statistical significance. However, 
nesiritide was associated with a small improvement of dys-
pnea, without significant effects on outcomes. Thus, ASCE-
ND-HF demonstrated that nesiritide is safe, but has only mild 
effects on symptoms, and no effects on outcomes.
70)
Neurohumoral Blockade
 Although, RAAS has an important role in renal dysfunc-
tion in acute HF syndrome, the role of the RAAS blockade 
with ACE inhibitors, angiotensin receptor blockers, direct re-
nin inhibitors, or aldosterone antagonists in acute progressive 
stage of renal dysfunction is unclear. Additionally, patients 
with diuretic resistance and advanced HF frequently show 
intolerance to the hemodynamic and renal effects of RAA an-
tagonists. Moreover, ACE inhibitors and angiotensin recep-
tor blockers can lead to an acute decrease in GFR through the 
dilatory effect on the efferent arteriole. Thus, in patients with 
acute decompensated HF, the risk of worsening renal function 
RAAS blockers were frequently hesitant to initiate them. 
However, the benefits of ACE inhibitors are clear, and out-
comes are extremely poor in individuals with HF in whom 
ACE inhibitors are held. In the Cooperative North Scandin-
avian Enalapril Survival Study, enalapril treated group show-
ed increased mean serum creatinine, but had lower mortality 
rates.
71) These data suggest that some increase in creatinine 
and reduction in GFR (up to 30%) using ACE inhibitors sh-
ould be tolerated even in patients with renal dysfunction. 
Ultrafiltration
Excess water can be removed by ultrafiltration using a se-
mipermeable membrane in response to a transmembrane 
pressure gradient between the blood and filtrate side. The 
removed fluid by ultrafiltration is isotonic to plasma, and 
isotonic fluid loss may be a potentially better tool for the tr-
eatment of congestion in patients with HF who have an acti-
vation of primarily sodium retentive mechanisms. Compared 
with loop diuretics, relatively more sodium can be removed 
by ultrafiltration. In case of diuretic resistance, ultrafiltration 
have been used to decrease excessive fluid overload and in 
patients with significantly decreased renal function, to correct 
abnormalities in electrolyte levels and acid-base status. In 
the Relief for Acutely Fluid-Overloaded Patients With Decom-
pensated Congestive Heart Failure there was marked weight 
loss and relief of HF symptoms, but no improvement of renal 
function.
72) In the Ultrafiltration versus Intravenous Diuretics 
for Patients Hospitalized for Acute Decompensated Heart 
Failure trial, there was a marked decrease in body weight, 
vasoactive drug requirement as well as hospital readmission 
over 90 days in the ultrafiltration arm.
73) However, this was 
associated with a trend towards higher-serum creatinine 
level in the first week of therapy in the ultrafiltration arm. The 
ongoing Cardiorenal Rescue Study in Acute Decompensated 
Heart Failure trial will further define the use of this treatment 
in patients with acute decompensated HF and acute renal dys-
function. 
Conclusions
For treatment of patients with acute HF, clinicians are fre-
quently faced with worsening renal dysfunction. The main dri-
ver of the pathophysiology and symptomatology is congestion 
and the focus of treatment should be relieving congestion 
without hemodynamic compromise. Unfortunately, every mo-
dality of treatment has dual effects - beneficial and detrimen-
tal - on this aspect. Loop diuretics relieve congestion but sti-
mulate the neurohormones and reduce GFR. Inotropes im-
prove hemodynamics but can potentially increase mortality 
and arrhythmias. Vasopressin antagonists have not been prov-
en to decrease mortality in a large randomized control trial, al-
though there are no large data sets on mixed receptor block-
ers. Natriuretic peptides may worsen kidney function and fail 
to show clinical benefit. Vasodilators can cause substantial 
hypotension while improving the hemodynamics. There-
fore, it might be impossible to provide guidelines containing 
beneficial treatment modalities based on robust evidence. Ac-
curate assessment for hemodynamic status with clinical pa-
rameters combined with newer biomarkers and more appro-
priate and effective interventions would help us to achieve 
optimal hemodynamic status and outcome of patients with 
acute HF syndrome. 
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